阿奇霉素序贯疗法对支原体肺炎患儿的影响

Effect of azithromycin sequential therapy on patients with mycoplasma pneumonia

目的探讨阿奇霉素序贯疗法对小儿支原体肺炎患者免疫功能、肺功能及趋化因子的影响。方法选取2015年5月—2017年5月收治的支原体肺炎患儿96例,采用随机数字表法将患者分为对照组与观察组各48例。两组均进行针对症状的常规治疗,对照组使用阿奇霉素注射液治疗,观察组采用阿奇霉素序贯疗法治疗。比较两组有效率、不良反应发生率、免疫功能指标、肺功能指标、趋化因子指标。计量资料比较采用t检验,计数资料比较采用χ2检验,P<0.05为差异有统计学意义。结果观察组总有效率(95.38%)高于对照组(89.58%),但差异无统计学意义(P>0.05)。观察组不良反应发生率(2.08%)低于对照组(12.5%)(P<0.05)。治疗后两组免疫功能指标、肺功能指标、趋化因子指标均高于治疗前(均P<0.05),但组间比较差异均无统计学意义(均P>0.05)。结论阿奇霉素序贯疗法治疗支原体肺炎可提高患儿免疫功能、降低体内趋化因子含量、改善患者肺功能,且可降低不良反应发生率。

Objective To explore the effect of azithromycin sequential therapy on immune function,pulmonary function and chemokines of children with mycoplasma pneumonia.Methods A total of 96 cases with mycoplasma pneumonia collected from May 2015 to May 2017 were randomly divided into control group and observation group（n=48） according to the digital table method.Control group received azithromycin injection while observation group were treated with azithromycin sequential therapy injection.After treatment,the effective rate,adverse reaction rate,immune function index,pulmonary function index and chemotactic factor index were compared between the two groups.Measurement data uses t test and count data uses χ~2 test,P〈0.05 is considered statistically significant.Results The total effective rate of the observation group was 95.38%,higher than that of the control group 89.58%,but there was no statistically significant difference between two groups（P〈0.05）.The incidence of adverse reactions in the observation group was 2.08%,which was lower than that of the control group（12.5%）（P〈0.05）.After treatment,immune function index,pulmonary function index,chemokine index of two groups were higher than before treatment（all P〈0.05）,but there was no significant difference between the two groups（P〈0.05）.Conclusion The sequential therapy of azithromycin in the treatment of mycoplasma pneumonia can improve the immune function,reduce the content of chemokines in the body,improve the lung function and reduce the incidence of adverse reactions.